Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.53 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.53 |
| ▸ | PARP1 | P09874 | 5/20 | 0.49 |
| ▸ | MAPT | P10636 | 5/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | AURKA | O14965 | 1/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.41 |
| ▸ | GRK6 | P43250 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10460075 | 0.82 | AKR1B1 (0.44) | MAPTALDH1A1RAB9AMAOAMAOB | |
| SCHEMBL7835016 | 0.79 | ADORA2A (0.51) | MAPTALDH1A1RAB9AMAOAMAOB | |
| SCHEMBL11057750 | 0.75 | AKR1B1 (0.57) | MAPTALDH1A1RAB9AMAOAMAOB | |
| SCHEMBL7833003 | 0.74 | MAOA (0.59) | MAPTALDH1A1RAB9AMAOAMAOB | |
| SCHEMBL343377 | 0.74 | ALDH1A1 (0.60) | MAPTALDH1A1RAB9AMAOAMAOB | |
| SCHEMBL10460076 | 0.74 | KDM4E (0.48) | MAPTALDH1A1RAB9AMAOAMAOB | |
| SCHEMBL343740 | 0.74 | MAOA (0.47) | MAPTALDH1A1RAB9AMAOAMAOB | |
| SCHEMBL7829487 | 0.73 | KEAP1 (0.73) | KEAP1NFE2L2MAPTALDH1A1GRK6 | |
| SCHEMBL7121384 | 0.73 | KEAP1 (0.86) | KEAP1NFE2L2MAPTALDH1A1MAOA | |
| SCHEMBL86392 | 0.72 | MAPT (0.67) | MAPTALDH1A1RAB9AMAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2393797-B1 | PROCESS FOR PREPARING OLOPATADINE AND/OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | ZACH SYSTEM SPA (IT) | 2016-04-20 | — | — | EP | disclosed |
| US-8835655-B2 | Process for preparing olopatadine and/or a pharmaceutically acceptable salt thereof | ZACH SYSTEM S.P.A (IT) | 2014-09-16 | — | — | US | disclosed |
| US-20120016138-A1 | PROCESS FOR PREPARING OLOPATADINE AND/OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | ZACH SYSTEM S.P.A. (IT) | 2012-01-19 | — | — | US | disclosed |
| EP-2393797-A2 | PROCESS FOR PREPARING OLOPATADINE AND/OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | ZaCh System S.p.A. (IT) | 2011-12-14 | — | — | EP | disclosed |
| WO-2010089268-A2 | PROCESS FOR PREPARING OLOPATADINE AND/OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | ZACH SYSTEM S.P.A. (IT) | 2010-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120016138-A1 | PROCESS FOR PREPARING OLOPATADINE AND/OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | QDPR, OPRD1, O60361 | KEAP1 2727/4885NFE2L2 3323/4885PARP1 3165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.